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Trichostatin A Inhibits Corneal Haze In Vitro and In Vivo
Ajay Sharma,1,2 Maneesh M. Mehan,1,2 Sunilima Sinha,1,2 John W. Cowden,1,2 and
Rajiv R. Mohan1,2,3
PURPOSE. Trichostatin A (TSA), a histone deacetylase inhibitor,
has been shown to suppress TGF-–induced fibrogenesis in
many nonocular tissues. The authors evaluated TSA cytotoxic-
ity and its antifibrogenic activity on TGF-–driven fibrosis in
the cornea with the use of in vitro and in vivo models.
METHODS. Human corneal fibroblasts (HSFs) were used for in
vitro studies, and New Zealand White rabbits were used for in
vivo studies. Haze in the rabbit cornea was produced with
photorefractive keratectomy (PRK) using excimer laser.
Trypan blue exclusion and MTT assays evaluated TSA cytotox-
icity to the cornea. Density of haze in the rabbit eye was graded
with slit lamp biomicroscopy. Real-time PCR, immunoblotting,
or immunocytochemistry was used to measure -smooth mus-
cle actin (SMA), fibronectin, and collagen type IV mRNA or
protein levels. TUNEL assay was used to detect cell death.
RESULTS. TSA concentrations of 250 nM or less were noncyto-
toxic and did not alter normal HSF morphology or prolifera-
tion. TGF-1 treatment of HSF significantly increased mRNA
and protein levels of SMA (9-fold), fibronectin (2.5-fold), and
collagen type IV (2-fold). TSA treatment showed 60% to 75%
decreases in TGF-1–induced SMA and fibronectin mRNA lev-
els and 1.5- to 3.0-fold decreases in protein levels but had no
effect on collagen type IV mRNA or protein levels in vitro.
Two-minute topical treatment of TSA on rabbit corneas subjected
to 9 D PRK significantly decreased corneal haze in vivo.
CONCLUSIONS. TSA inhibits TGF-1–induced accumulation of
extracellular matrix and myofibroblast formation in the human
cornea in vitro and markedly decreases haze in rabbit cornea in
vivo. (Invest Ophthalmol Vis Sci. 2009;50:2695–2701) DOI:
10.1167/iovs.08-2919
L aser surgical procedures such as laser-assisted in situ kera-tomileusis (LASIK), photorefractive keratectomy (PRK),
and laser epithelial keratomileusis (LASEK) are widely used for
correcting refractive errors in the United States and around the
world.1–3 LASIK is the most popular procedure because it
involves less pain, faster postoperative recovery, and lower
wound-healing response.4–6 Nonetheless, a significant propor-
tion of patients experience various side effects from LASIK that
raise questions about the safety of this procedure.2,7 Recently,
the United States Food and Drug Administration formed a
LASIK study task force to address side effects as an outcome of
LASIK.8 Unlike LASIK, PRK does not involve corneal flap for-
mation and, in some patients, is the procedure of choice.9
However, complications such as postoperative pain and haze
have been reported in patients receiving PRK correction for
high myopia.10,11 Mitomycin C (MMC) is increasingly used by
clinicians to treat corneal haze.12–14 The potency of MMC to
inhibit corneal haze has been shown by many clinical and
experimental studies.13–15 However, multiple complications
such as limbal/scleral necrosis, corneal endothelial damage, ab-
normal wound healing, loss of keratocytes, and endothelial dam-
age are reported with the topical use of MMC.16–19 We have
recently shown that topical application of MMC prevents the
repopulation of keratocytes and creates an acellular zone in the
rabbit cornea because no keratocyte proliferation was noted even
up to 6 months.20 These reports expose the risks of using MMC to
treat corneal haze in patients and encourage the development of
newer pharmacologic agents that can effectively inhibit the for-
mation of corneal haze without causing serious side effects.
Multiple in vitro and in vivo studies performed in experi-
mental animals have significantly increased our understanding
of the cellular and molecular mechanisms involved in haze
development after PRK.21,22 PRK causes an alteration in the
natural conformation of extracellular matrix and changes the
cellular density and phenotype of keratocytes.21 These factors
result in decreased corneal tissue transparency, commonly
referred to as corneal haze or opacity.22 The generation of
corneal myofibroblasts has recently been identified as the pri-
mary biological event responsible for the formation of corneal
haze.21,23,24 Myofibroblasts are highly contractile cells with
reduced transparency attributable to decreased intracellular
crystallin production.25 Various cytokines and chemokines
have also been implicated as playing important roles in corneal
wound healing after PRK.26–28 Of the many cytokines shown
to modulate corneal wound healing, TGF- plays a central role
in haze development.21,29,30 It triggers the transformation of
quiescent keratocytes into corneal fibroblasts and myofibro-
blasts.31It also stimulates the de novo synthesis of the extra-
cellular matrix proteins.32 Thus, it was hypothesized that
agents with TGF- inactivation or neutralization properties can
inhibit haze development in the cornea in vivo.
TGF- signal transduction from the cell surface to the nu-
cleus is mediated largely by the Smad family of intracellular
proteins.30 Recent research suggests that Smad-mediated gene
expression may be affected by histone acetylation.33,34 Histone
acetylation and deacetylation are regulated by opposing activ-
ities of two enzymes, histone acetylase (HAT) and histone
deacetylase (HDAC). These enzymes affect gene transcription
by altering chromatin structure35 and, therefore, play a critical
role in the epigenetic regulation of gene transcription.36 The
HDAC enzymes are grouped into three classes. Class I and class
II HDACs are implicated in the regulation of gene transcription,
but the significance of class III HDACs is still unclear.36
Trichostatin A (TSA), a fermentation product derived from
the cultures of Streptomyces species, is a reversible inhibitor of
class I and class II HDACs.34,37 TSA received special attention
because it inhibits HDACs in low nanomolar concentrations
compared with other known HDAC inhibitors, which work at
high micromolar concentrations.37 Because of its potency,
several derivatives are at various stages of clinical development
to treat cancer.36 Recent reports have demonstrated that TSA
inhibits TGF-1–mediated synthesis of collagen, -smooth mus-
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cle actin (SMA), and myofibroblast transformation of hepatic38
and skin fibroblasts.39 These TSA-mediated effects are accom-
panied by hyperacetylation of H3 and H4 histones.38,39 HDAC-
dependent prevention of TGF-1–mediated transformation of
fibroblasts into myofibroblasts has also been confirmed using
siRNA-mediated approaches and other pharmacologic inhibi-
tors.34 Although the exact mechanism of TSA-mediated inhibi-
tion of TGF- effects has not been fully elucidated, TSA has
been shown to increase the levels of Smad7, 5-TG-3-interact-
ing factor (TGIF), and TGIF2.34,39 Smad7 and TGIF are well
documented repressors of TGF-–mediated signal transduction.
TSA has also been reported to inhibit the interaction of Smad
proteins with transcription factors such as zinc finger binding
protein Sp1 and p300.40 These transcription factors, along with
Smad, bind to the promoter region of TGF-–regulated genes.
Therefore, TSA-mediated inhibition of these transcription factors
will abrogate TGF-–mediated gene expression. These reports
prompted us to hypothesize that suppression of TGF-–in-
duced profibrotic genes with trichostatin A may be a novel
approach to treat or prevent PRK-induced corneal haze.
MATERIALS AND METHODS
Human Corneal Fibroblast Culture
Donor human corneas were procured from an eye bank and were used
in the study in accordance with the Declaration of Helsinki for the use
of human tissue. Primary human corneal fibroblasts were generated
from donor human corneas according to a method described previous-
ly.41 Briefly, the cornea was washed with cell culture medium, and the
epithelium and endothelium were removed by gentle scraping with a
scalpel blade. Corneal stroma was cut into small pieces and incubated
in a humidified CO2 incubator at 37°C in Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum to obtain human corneal
fibroblasts. Seventy percent confluent cultures of human corneal fibro-
blasts (passages 1–3) were used for experiments. For myofibroblast
generation, cultures were exposed to TGF-1 (1 ng/mL) for 7 days
under serum-free conditions. TSA was used at 50 to 500 nM concen-
trations. TGF-1 was purchased from R&D Systems (Minneapolis, MN),
and TSA was purchased from Sigma-Aldrich (St Louis, MO).
RNA Extraction, cDNA Synthesis, and Quantitative
Real-Time PCR
Total RNA from the cells was extracted with a purification kit (RNeasy
kit; Qiagen Inc., Valencia, CA) and was reverse transcribed to cDNA in
accordance with the manufacturer’s instructions (ImProm-II Reverse
Transcription system; Promega, Madison, WI). Real-time PCR was per-
formed (iQ5 Real-Time PCR Detection System; Bio-Rad Laboratories,
Hercules, CA). A 50-L reaction mixture containing 2 L cDNA (250
ng), 2 L forward primer (200 nM), 2 L reverse primer (200 nM), and 25
L 2 green super mix (iQ SYBR; Bio-Rad Laboratories) was run at a
universal cycle (95°C for 3 minutes, 40 cycles at 95°C for 30 seconds, and
60°C for 60 seconds) in accordance with the manufacturer’s instructions.
For SMA, the forward primer sequence TGGGTGACGAAGCACAGAGC
and the reverse primer sequence CTTCAGGGGCAACACGAAGC were
used. For fibronectin, the forward primer sequence was CGCAGCTTC-
GAGATCAGTGC, and the reverse primer sequence was TCGACGGGAT-
CACACTTCCA. For type IV collagen, the forward primer sequence of
AGGTGTTGACGGCTTACCTG and the reverse primer sequence of
TTGAGTCCCGGTAGACCAAC were used for real-time PCR. -Actin
forward primer (CGGCTACAGCTTCACCACCA) and reverse primer
(CGGGCAGCTCGTAGCTCTTC) were used as housekeeping genes.
Cycle threshold (Ct) was used to detect the increase in the signal
associated with an exponential growth of PCR product during the
log-linear phase. Relative expression was calculated with 2-Ct. Ct
validation experiments showed similar amplification efficiency for all
templates used (difference between linear slopes for all templates 
0.1). Three independent experiments were performed, and the aver-
age (SEM) results are presented in graphic form.
Immunoblotting
Cells were washed with ice-cold PBS and lysed directly onto plates
with RIPA protein lysis buffer containing protease inhibitor cocktail
(Roche Applied Sciences, Indianapolis, IN). Samples were suspended
in Laemmli denaturing sample buffer (30 L) containing -mercapto-
ethanol, vortexed for 1 minute, centrifuged for 5 minutes at 10,000g,
and boiled at 70°C for 10 minutes. Protein samples were resolved by
4% to 10% SDS-PAGE and were transferred to a 0.45-m pore size
polyvinylidene difluoride membrane (Invitrogen, San Diego, CA). The
membrane was incubated with SMA (Dako, Carpinteria, CA), fibronec-
tin, or GAPDH primary antibodies (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) followed by secondary anti-mouse or anti-goat anti-
bodies (Santa Cruz Biotechnology).
Cell Proliferation Assay
To assess the effect of TSA treatment on corneal fibroblast prolifera-
tion, the number of viable cells was counted according to an MTT-
based method, as described previously.42 The assay uses a tetrazolium
compound, MTT (Sigma-Aldrich), that is bioreduced by viable cells to
a purple formazan product (proportional to the number of viable cells)
and can be detected by measuring absorbance at 570 nm. With the use
of a 96-well plate, 2 103 cells/well were plated in 100 L DMEM, and
10 L MTT reagent was added to each well. Wells containing media
alone, without cells, served as negative controls. The plates were
incubated for various amounts of time at 37°C in a humidified 5% CO2
incubator. To study the effect of TSA on cell growth, 50 to 500 nM TSA
was added to each well. Absorbance was recorded at 570 nm with a
96-well plate reader (FLx 800; BioTEk, Winooski, VT).
Corneal Haze Generation and TSA Application
Twelve female New Zealand White rabbits, each weighing 2.5 to 3.0
kg, were included in this study. All animals were treated in accordance
with the tenets of the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research. Animals were anesthetized by intra-
muscular injection of ketamine hydrochloride (40 mg/kg) and xylazine
hydrochloride (5 mg/kg). In addition, topical proparacaine hydrochlo-
ride 0.5% (Alcon, Fort Worth, TX) was applied to each eye just before
surgery. With the animal under general and local anesthesia, a wire lid
speculum was positioned, and a 7-mm diameter area of epithelium
overlying the pupil was removed by scraping with a no. 64 blade
(Beaver; Becton-Dickinson, Franklin Lakes, NJ). Corneal haze was in-
duced by performing 9.0 D PRK with a 6-mm ablation zone on the
central stroma with an excimer laser (Summit Apex; Alcon). Only one
eye from each animal was used for the surgical procedure; the con-
tralateral eye served as the naive control. Animals were divided into
two groups consisting of control and TSA-treated animals. In the
TSA-treated group, a topical 0.02% solution of TSA was applied for 2
minutes immediately after PRK, followed by copious washing with
balanced salt solution (BSS; Alcon, Ltd., Ft. Worth, TX).
Biomicroscopic Grading of Corneal Haze
The level of opacity (haze) in the cornea was measured with slit lamp
4 weeks after PRK according to a method reported previously43 with
animals under general anesthesia. Grade 0 was a completely clear
cornea; grade 0.5 had trace haze seen with careful oblique illumination
with slit lamp biomicroscopy; grade 1 was more prominent haze not
interfering with the visibility of fine iris details; grade 2 was mild
obscuration of iris details; grade 3 was moderate obscuration of the iris
and lens; and grade 4 was complete opacification of the stroma in the
area of the ablation. Haze grading was performed in a masked manner.
Tissue Collection
Rabbits were euthanatized with overdoses of pentobarbitone (100
mg/kg) while still under ketamine/xylazine anesthesia. Corneas were
removed with forceps and sharp Westcott scissors, embedded in liquid
optimal cutting temperature compound (Sakura FineTek, Torrance,
CA) within a 24  24  5-mm mold (Fisher, Pittsburgh, PA), and snap
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frozen. Frozen tissue blocks were maintained at 80°C. Tissue sec-
tions (7 m) were cut with a cryostat (CM 1850; Leica, Wetzlar,
Germany) Sections were placed on 25 75 1-mm microscope slides
(Superfrost Plus; Fisher, Pittsburgh, PA) and were maintained frozen at
80°C until staining was performed.
TUNEL and Immunohistochemistry Assays
For TUNEL assay, tissue sections were fixed in acetone at20°C for 10
minutes, dried at room temperature for 5 minutes, and placed in PBS
BSS. Fluorescent apoptosis detection assay (ApopTag; Chemicon Inter-
national, Temecula, CA) that detects apoptosis and, to a lesser extent,
necrosis was performed in accordance with the manufacturer’s in-
structions. Positive (4 hours after mechanical corneal scrape) and
negative (unwounded) control slides were included in each assay.
Immunofluorescence staining for -SMA, a marker for myofibro-
blasts, was performed using mouse monoclonal antibody for SMA
(catalog no. M0851; Dako, Carpinteria, CA). Tissue sections (7 m)
were incubated at room temperature with the monoclonal antibody for
SMA at a 1:200 dilution in 1 PBS for 90 minutes and with secondary
antibody Alexa 488 goat anti-mouse IgG (catalog no. A11001; Invitro-
gen) at a dilution of 1:500 for 1 hour. For collagen type IV immuno-
staining, rat monoclonal AbH11, AbH22 (generous gift from Nirmala
Sundarraj, University of Pittsburgh, Pittsburgh, PA), and goat poly-
clonal antibody (catalog no. sc9302; Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) were used at 1:100 dilutions for 2 hours. Appropriate
Alexa 594 secondary antibodies (catalog nos. A-11058 and A-11007;
Invitrogen) were used at a dilution of 1:500 for 1 hour. For fibronectin
immunostaining, goat polyclonal primary antibody (catalog no. sc6952;
Santa Cruz Biotechnology) was used. Tissues were incubated at room
temperature at 1:200 dilution for 90 minutes, followed by secondary
antibody Alexa 594 donkey anti-goat IgG (catalog no. A11058; Invitro-
gen) at a dilution of 1:500 for 1 hour. Tissues were mounted with
mounting medium containing DAPI (catalog no. H1200; Vectashield;
Vector Laboratories, Inc. Burlingame, CA) to visualize nuclei in the
tissue sections. Irrelevant isotype-matched primary antibody, second-
ary antibody alone, and tissue sections from naive eyes were used as
negative controls for each immunocytochemistry experiment. Sections
were viewed and photographed with a fluorescence microscope
(Leica) equipped with a digital camera (SpotCam RT KE; Diagnostic
Instruments Inc., Sterling Heights, MI).
Quantification of SMA-Positive Cells
SMA-positive cells in six randomly selected, nonoverlapping, full-thick-
ness central corneal columns extending from the anterior stromal
surface to the posterior stromal surface were counted according to a
method reported previously.44 The diameter of each column was a
400 microscope field.
Image and Statistical Analyses
Results were expressed as mean SEM. Statistical analysis was performed
with two-way analysis of variance (ANOVA) followed by Bonferroni mul-
tiple comparisons test for cell toxicity assay. Real-time PCR data results
were analyzed with one-way ANOVA followed by Tukey multiple com-
parison tests. Corneal haze quantification data were analyzed with non-
parametric one-way ANOVA with Wilcoxon rank sum test. P  0.05 was
considered significant. Gel data were analyzed with ImageJ 1.38 X image
analysis software (developed by Wayne Rasband, National Institutes of
Health, Bethesda, MD; available at http://rsb.info.nih.gov/ij/index.html).
RESULTS
Effect of TSA on Cell Viability
To assess any potential toxicity of TSA treatment, we evaluated
the time-dependent effect of four different concentrations of
TSA on cell viability with the use of cultured human corneal
fibroblasts. As seen in Figure 1, of the four tested concentra-
tions of TSA, three (50, 100, 250 nM) had no significant effect
on the percentage of live cells up to the tested time point of 72
hours. TSA caused a decrease in the live cell count only at the
500-nM dose (18% P  0.01) at 72 hours (Fig. 1).
FIGURE 1. Time- and dose-dependent cytotoxicity of TSA to cultured
human corneal fibroblasts. Cultures were exposed to different concen-
trations of TSA (50, 100, 250, 500 nM) for 72 hours, and cell viability
was quantified with MTT or trypan blue assay at 8, 24, 48, or 72 hours.
TSA did not produce any cytotoxic effect on the cultured fibroblasts.
Data are shown as mean  SEM of percentage live cells. *P  0.01
versus control.
FIGURE 2. Real-time quantitative PCR showing differential change in SMA (left), fibronectin (middle), and
collagen type IV (right) expression in human corneal fibroblast cultures exposed to TGF-1 (1 ng/mL) for
7 days under serum-free conditions with or without TSA. TGF-1 caused a 9-fold increase in SMA, a 2.5-fold
increase in fibronectin, and a 2-fold increase in collagen type IV levels. TSA treatment inhibited TGF-1–
induced SMA and fibronectin expression significantly. *P  0.01 versus control; **P  0.01 versus TGF-1
treatment; ***P  0.001 versus control.
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Effect of TSA Treatment on TGF-1–Mediated
Myofibroblast Generation in Cultured Human
Corneal Fibroblasts
We quantified mRNA and protein levels of -SMA, a marker of
myofibroblasts, in human corneal fibroblasts with real-time
PCR, Western blotting, and immunohistochemistry. TGF-1
treatment of cultured human corneal fibroblasts resulted in a
9-fold increase (P 0.001) in SMA mRNA levels. TSA treatment
of cultured human corneal fibroblasts at 100 and 250 nM
caused 60% (P  0.01) and 75% (P  0.01) reductions, respec-
tively, in TGF-1–mediated increased levels of SMA (Fig. 2).
Western blot analysis of TGF-1–treated human corneal fibro-
blasts revealed a significant increase in protein levels of SMA.
Trichostatin treatment caused 2-fold (100-nM dose) and 3-fold
(250-nM dose) decreases in TGF-1–induced levels of SMA
(Fig. 3). These results were further complemented by SMA
immunohistochemical staining, demonstrating a significant de-
crease in SMA-stained cells in TSA-treated human corneal fibro-
blasts (Fig. 3) compared with TGF-1–treated controls.
Effect of TSA Treatment on TGF-1–Mediated
Alteration of Extracellular Matrix Proteins in
Cultured Human Corneal Fibroblasts
To evaluate the effect of TSA treatment on TGF-1–induced alter-
ations of extracellular matrix proteins, we quantified mRNA and
protein levels of fibronectin and collagen type IV using real-time
PCR and Western blotting. TGF-1 treatment of cultured human
corneal fibroblasts caused a 2.5-fold increase (P  0.01) in fi-
bronectin mRNA level (Fig. 2). Additionally, TGF-1 also caused a
significant increase in fibronectin protein level, as quantified by
Western blot analysis. TSA (100 nM, 250 nM) treatment of these
corneal fibroblasts caused a 60% to 64% (P  0.01) reduction in
TGF-1–mediated increased levels of fibronectin mRNA and a
1.5-fold (250-nM dose) decrease in TGF-1–mediated increased
levels of fibronectin protein levels (Fig. 3).
TGF-1 stimulation of cultured human corneal fibroblasts
resulted in a 2-fold increase (P  0.01) in collagen type IV
mRNA as revealed by real-time PCR. TSA treatment of these
TGF-1–treated HSFs did not cause any significant change in
collagen type IV mRNA levels (Fig. 2).
Slit Lamp Biomicroscopy Evaluation of TSA
Treatment on PRK-Induced Corneal Haze
Corneal haze was evaluated with slit lamp biomicroscopy 4
weeks after9 D PRK. The 4-week point was chosen based on
the results of our previous studies in which we noticed peak
corneal haze at this time.20,22,44 Control corneas subjected to
9 D PRK had an average haze of 3.5 on the Fantes scale.
Topical application of TSA (0.02% for 2 minutes) caused a
statistically significant decrease (P  0.01) in corneal haze,
with an average score of 1 on the Fantes scale (Fig. 4B). No
corneal haze was noted in untreated control corneas, which
were not subjected to PRK treatment (Fig. 4A).
Effect of TSA Treatment on PRK-Induced
Myofibroblast Generation in Rabbit Corneas
The formation of haze in rabbit corneas was also confirmed by
the immunocytochemical detection of myofibroblasts (Figs.
5A, 5B) and quantification of SMA-positive cells in tissue sec-
tions. No SMA-positive cells were observed in untreated con-
trol corneas. In contrast, rabbit corneas collected 4 weeks after
9 D PRK demonstrated high numbers of SMA-positive myo-
fibroblast cells, mostly in the anterior stroma below the epi-
thelium. Two-minute topical TSA application immediately after
PRK significantly (60%; P  0.01) reduced the number of
SMA-positive cells in the rabbit stroma (Fig. 6).
Effect of TSA Treatment on PRK-Induced
Alteration of Extracellular Matrix Proteins in
Rabbit Corneas
Immunohistochemical staining for fibronectin was noted in the
stromas of the rabbit corneas subjected to9 D PRK. Fibronec-
tin expression was confined to the zone of laser photoablation,
FIGURE 3. Immunocytochemistry (left, middle) and immunoblotting (right) analyses showed significant
decreases in myofibroblast formation by TSA in corneal fibroblast cultures grown in the presence of
TGF-1 (1 ng/mL) under serum-free conditions. Cell nuclei are stained blue with DAPI, and SMA-positive
cells are stained green. Equal quantity of protein was loaded in each lane. GAPDH was used as a
housekeeping gene. TSA treatment showed a significant 3-fold decrease in SMA and a 1.5-fold decrease in
fibronectin expression. Scale bar, 100 m.
FIGURE 4. (A) Representative slit
lamp microscopy images demonstrat-
ing density and location of haze in con-
trol (left), PRK-treated (right), and
PRK0.02% TSA–treated (middle) rab-
bit corneas. (B) Biomicroscopic quan-
tification of corneal haze. A significant
decrease in corneal haze was observed
in TSA-treated corneas (P  0.01).
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with a sharp demarcation between ablated and nonablated
zones. In the ablated zone positively stained for SMA, fibronec-
tin expression was noted in the anterior stroma, and it colo-
calized around SMA-positive cells. In the rest of the anterior
stroma, which did not stain for SMA, fibronectin distribution
was observed only around the area of basement membrane,
just below the epithelium. TSA treatment markedly decreased
fibronectin expression in the anterior stroma of PRK-treated
rabbit corneas (Figs. 5C, 5D).
Immunohistochemical staining for collagen type IV per-
formed with rat monoclonal antibodies detected collagen type
IV 1 (Figs. 5E, 5F) and 2 subtypes (data not shown) in rabbit
corneal epithelial basement membrane. However, immuno-
staining performed with a commercial antibody (sc9302; Santa
Cruz Biotechnology) detected collagen type IV 5 expression
in the stroma but was unable to recognize collagen type IV 1
in epithelial basement membrane (data not shown). None of
the collagen immunohistochemistry experiments showed ap-
preciable changes in collagen type IV levels in the PRK-treated
rabbit corneas, with or without TSA application (Figs. 5E, 5F).
Effect of TSA on Cell Death in Rabbit Corneas
Subjected to 9 D PRK
We further evaluated the effect of TSA treatment on cell death
using TUNEL assay. Few TUNEL-positive cells were noted in
the stroma and epithelium in control corneas subjected to 9
D PRK (Fig. 7). Topical application of TSA in corneas subjected
to 9 D PRK caused no further change in TUNEL-positive cells
in stroma or epithelium. To examine any change in keratocyte
density attributed to cell death caused by TSA, we compared
the number of DAPI-stained nuclei in the sections obtained from
rabbit corneas subjected to 9 D PRK followed by 2-minute
topical application of 0.02% TSA or no TSA. No significant differ-
ence in keratocyte cell density was observed in TSA-treated or
control corneas subjected to 9 D PRK, suggesting that TSA
application did not cause cell death (data not shown).
DISCUSSION
Corneal haze is a common complication of PRK.10,13,15 Corneal
wound healing response to refractive surgery is proposed as
the underlying mechanism for haze formation.45,46 Therefore,
attention has been focused on the use of therapeutic agents to
modulate postoperative wound healing. MMC is a DNA-alkylat-
ing agent and is widely used intraoperatively by clinicians for
the prevention of PRK-induced corneal haze.12–15 Although
MMC is effective in controlling haze, there are safety concerns
because of several complications reported with its topical use,
such as limbal/scleral necrosis, corneal endothelial damage,
abnormal wound healing, and loss of keratocytes.16–19 Thus,
there is a need for safer therapeutic agents to treat corneal
haze. In the present study, we demonstrate that TSA has an
antifibrogenic effect in cultured human corneal fibroblasts ex-
posed to TGF-1 and prevents corneal haze in vivo in rabbit
corneas subjected to 9 D PRK.
TSA is a potent and reversible HDAC inhibitor.37 HDAC and
HAT are key enzymes that regulate the acetylation of histone
proteins.36 Histones are core proteins around which DNA is
coiled to form a compact chromatin structure. Acetylation of
histone proteins causes the chromatin structure to uncoil,
making it more accessible to transcription factors.35 Accumu-
lating evidence suggests that histone acetylation by HDAC
enzymes plays a critical role in the regulation of gene transcrip-
tion, and pharmacologic inhibitors of HDAC such as TSA have
been used to modulate gene expression in a variety of disease
conditions (cancer,36 lupus,47 cardiac hypertrophy,48 spinal
FIGURE 7. TUNEL assay of the central cornea from rabbits that under-
went 9 D PRK with or without topical application of 0.02% TSA.
Nuclei are stained blue with DAPI. Few TUNEL-positive cells (red)
were seen in the epithelium. No loss of keratocytes (blue-stained
nuclei) was noted in TSA-treated versus control (no TSA) rabbit cor-
neas collected 4 weeks after 9 D PRK. Arrows: TUNEL-positive cells.
Scale bar, 100 m.
FIGURE 5. Representative immunohistochemistry images of corneal
tissue sections showing levels of SMA (A, B), fibronectin (C, D), and
collagen type IV (E, F) in rabbit corneas collected 4 weeks after 9 D
PRK with or without TSA application. DAPI-stained nuclei are shown in
blue, SMA-stained cells are shown in green, and fibronectin or collagen
type IV-positive cells are shown in red. TSA-treated corneas showed
significant decreases in SMA (B; P  0.01) and notable decreases in
fibronectin levels in the stroma compared with control corneas (A, C).
No significant change was noted in collagen type IV (E, F). Arrows:
positive protein immunostaining. Scale bar, 100 m.
FIGURE 6. Quantification of SMA-positive cells/400 column in the
tissue section obtained from rabbit corneas that underwent 9 D PRK
with or without topical application of 0.02% TSA. TSA treatment
decreased SMA-positive cells by 60% (P  0.01).
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muscular dystrophy).49 The initial evidence that TSA has anti-
fibrotic effects came from studies by Rombouts et al.,38 who
demonstrated that TSA caused a significant decrease in the
expression of profibrotic genes such SMA, collagen type I, and
collagen type III in cultured hepatic stellate cells because of
the hyperacetylation of histone H4.38 Several of these profi-
brotic genes have a TGF- response element in their promoter
region.50,51 Jester et al.31 demonstrated that the incubation of
corneal fibroblasts with TGF- transforms them into myofibro-
blasts and causes increased expression of profibrotic genes
such as extracellular matrix proteins and cytoskeletal proteins
such as collagen, fibronectin, and SMA. A recent report has
demonstrated that silencing of HDAC4 with siRNA prevents
TGF-–mediated transformation of skin fibroblasts into myofi-
broblasts,34 thereby directly implicating HDAC in TGF-–me-
diated fibrosis.34 These studies led us to propose that HDAC
inhibitors may block or prevent the TGF-–mediated transdif-
ferentiation of corneal fibroblasts into myofibroblasts. We
tested this hypothesis with cultured human corneal fibroblasts
and showed that TSA (a potent HDAC inhibitor) prevents
TGF-1–mediated transformation of corneal fibroblasts into
myofibroblasts and significantly decreases TGF-1–induced
gene expression of SMA and fibronectin.
The precise mechanism through which TSA blocks TGF-1–
mediated gene expression has not yet been completely eluci-
dated. However, three potential mechanisms have been pro-
posed. First, TSA-induced hyperacetylation directly inhibits the
expression of some of the TGF-–regulated genes such as
procollagen  type III and SMA.38–40 Second, TSA increases
the expression of Smad7 and TGIF proteins. These proteins are
suggested to be involved in blocking Smad signaling, affecting
some other genes such as procollagen  type I.34,39 Third, TSA
affects the expression of transcription factors such as p300/
CBP, which act as cofactors in TGF--Smad–mediated gene
expression.40 Nonetheless, not all the genes activated by
TGF- are blocked by TSA, and the expression levels of some
genes, such as collagen type IV38 and PAI-1, remain unaffect-
ed.40 We observed that in corneal fibroblasts, TSA decreased
TGF-1–induced gene expression of fibronectin and SMA but
did not alter the expression of collagen type IV. These obser-
vations suggest that HDAC inhibitors may not affect global
gene expression in human corneal fibroblasts. Earlier studies
using cultured lymphocytes confirmed that TSA affects only
approximately 2% of the cellular genes, as shown by differen-
tial gene display experiments.52 Future studies will investigate
the molecular basis of the selectivity of TSA-mediated gene
expression in cornea.
The formation of corneal haze involves the apoptosis of
keratocytes and the proliferation and transformation of fibro-
blasts into myofibroblasts.53 These cellular changes are accom-
panied by SMA expression and the deposition of disorganized
extracellular matrix proteins that are primarily responsible for
corneal fibrosis and opacity.21,45 Multiple studies show that
TGF- mRNA and its receptors are upregulated after PRK.54,55
Jester et al.56 have demonstrated the prevention of PRK-in-
duced haze in experimental animals with the use of anti–TGF-
antibodies. Antisense approaches targeted to neutralizing
TGF- further confirm its involvement in ocular fibrosis.57
These reports implicate the role of TGF- in PRK-induced
corneal haze. Several in vitro reports demonstrate that the
biological effects of TGF- can be blocked by TSA. Our cell
culture experiments performed with TSA showed that TSA
prevents the TGF-1–induced transformation of corneal fibro-
blasts into myofibroblasts. Thus, we tested the effect of TSA in
an in vivo rabbit model of PRK-induced corneal haze. We found
that a single 2-minute application of 0.02% TSA immediately
after PRK markedly reduces laser-induced corneal haze in rab-
bit eyes. Slit lamp biomicroscopy experiments show that TSA
markedly decreases corneal opacity. Immunohistochemistry
analysis revealed a decrease in the expression of -SMA, a
marker of myofibroblast formation and fibronectin, but no
change in collagen expression. Based on our in vitro experi-
ment results and our earlier experience with MMC, a single
0.02% dose of TSA was tested in this study. Further studies are
needed to define the optimal dose of TSA showing minimal
toxicity and maximal therapeutic effect. Although TSA is not
approved for use in humans, vorinostat, a TSA structural deriv-
ative, is already in clinical use for the treatment of T-cell
lymphoma,58 and our study opens up the possibility of testing
HDAC inhibitors in ophthalmology for clinical use.
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